Importance of cytokeratin-20 expression in papillary urothelial neoplasia

Year 2020, Volume: 45 Issue: 4, 1326 - 1332, 27.12.2020

Onur Ceylan İbrahim Karabulut

https://doi.org/10.17826/cumj.714836

Abstract

Purpose: The aim of this study is to determine the role of Cytokeratin 20 (CK20) expression in the diagnosis of papillary urothelial neoplasms of the bladder, and its relationship with histological grade, recurrence and other prognostic factors.
Materials and Methods: Patients diagnosed with papillary urothelial neoplasm of bladder transurethral resection (TUR) specimens between January 2011 and December 2016 were retrospectively analyzed. Of the 136 selected patients, 32 (24%) were diagnosed with urothelial papilloma, 8 (6%) with papillary urothelial neoplasm of low malignant potential (PUNLMP), 36 (26%) with low grade non-invasive papillary urothelial carcinoma (LGNIPUC), 12 (9%) with high grade non-invasive papillary urothelial carcinoma (HGNIPUC) and 48 (35%) were diagnosed with high grade invasive papillary urothelial carcinoma (HGIPUC). There was no patient diagnosed with LGIPUC. The correlation between CK20 expression and histological grade, tumor recurrence, presence of progression and presence/absence of invasion was investigated.
Results: There was a significant difference between PUNLMP and LGNIPUK in terms of CK20 expression in favor of LGNIPUK. Also there was a significant correlation between histological grade, presence of invasion, recurrence, progression and CK20 expression in patients diagnosed with Papillary Urothelial Neoplasm.
Conclusion: This study supports that CK20 is an important marker in the differentiation between PUNLMP and LGNIPUC, as well as in the determination of histological grade in urothelial carcinomas.

Keywords

Papillary Urothelial Neoplasm, CK20 Expression, Prognostic Markers

Supporting Institution

None to declare

Thanks

No acknowledgement to declare.

Papiller ürotelyal neoplazilerde sitokeratin-20 ekspresyonunun önemi

Abstract

Amaç: Bu çalışmanın amacı, mesanenin papiller ürotelyal neoplazilerinde önemli bir immünhistokimyasal belirteç olan Sitokeratin 20 (CK20) ekspresyonunun tanıdaki rolünü, histolojik grade, nüks ve diğer prognostik faktörler ile ilişkisini belirlemektir.
Gereç ve Yöntem: Ocak 2011 ile Aralık 2016 tarihleri arasındaki mesane transüretral rezeksiyon (TUR) spesmenlerine ait papiller ürotelyal neoplazi tanısı almış olgular retrospektif olarak incelendi. Seçilen 136 hastadan 32'si (% 24) ürotelyal papillom, 8'i (%6) malignite potansiyeli belirsiz papiller ürotelyal neoplazi (PUNLMP), 36'sı (%26) low grade non invaziv papiller ürotelyal karsinom (LGNİPÜK), 12'si (%9) high grade non invaziv papiller ürotelyal karsinom (HGNIPÜK) ve 48'i (% 35) high grade invaziv papiller ürotelyal karsinom (HGIPÜK) tanısı almıştı. Low grade invaziv papiller ürotelyal karsinom tanısı alan hasta yoktu. CK20 ekspresyonu ile histolojik grade, tümör nüksü, progresyon varlığı ve invazyon varlığı/yokluğu arasındaki ilişki araştırıldı.
Bulgular: PUNLMP ve LGNİPÜK arasında LGNIPÜK lehine CK20 ekspresyonu açısından önemli fark vardı. Ayrıca Papiller Ürotelyal Neoplazi tanısı alan vakalarda histolojik grade, invazyon varlığı, nüks ve progresyon ile CK20 ekspresyonu arasında anlamlı ilişki bulundu.
Sonuç: Bu çalışma CK20’ nin gerek PUNLMP ve LGNİPUK ayrımında gerekse Ürotelyal Karsinomlarda histolojik grade belirlenmesinde önemli bir belirteç olduğunu desteklemektedir.

Keywords

Papiller Ürotelyal Neoplazm, CK20 Ekspresyonu, Prognostik Belirteçler

References

• 1- Moch H, Humphrey PA, Ulbright TM, Reuter VE. Tumours of the urinary tract. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, Editor. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed. Lyon, France: IARC Press; 2016. p.77-106.
• 2- Arias-Stella JA, Shah AB, Gupta NS, Williamson SR. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens with Equivocal Atypia. Arch Pathol Lab Med. 2018; 142:64-9.
• 3- Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts BE et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999; 85: 2469-74.
• 4- Ogata DC, Marcondes CA, Tuon FF, Busato WF Jr, Cavalli G, Czeczko LE. Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression. Rev Col Bras Cir. 2012; 39: 394-400.
• 5- Wang G, McKenney JK. Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med. 2019; 143: 571-7.
• 6- Mallofr´e C, Castillo M, Morente V, Sol ´e M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathology 2003; 16: 187–91.
• 7- Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology. Mod Pathol. 2001; 14: 267-72.
• 8- Moll R. Molecular diversity of cytokeratin: significance for cell and tumor differentiation. Acta Histochem Suppl. 1991; 4:117–27.
• 9- Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996; 78: 870–5.
• 10- Rajcani J, Kajo K, Adamkov M, Moravekova E, Lauko L, Felcanova D et al. Immunohistochemical characterization of urothelial carcinoma. Bratisl Lek Listy. 2013; 114: 431-8.
• 11- Ramos D, Navarro S, Villamón R, Gil-Salom M, Llombart-Bosch A. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer. 2003; 97: 1876-83.
• 12- Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC). J Cancer. 2017; 8: 2885-91.
• 13- Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010; 60: 1-8.
• 14- Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010; 133: 788-95.
• 15- Alrashidy M, Atef A, Baky TA. Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder. Asian Pac J Cancer Prev. 2016; 17: 1769-72.
• 16- Van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E. FGFR3 mutations and a normal CK20 staining pattern define low-grade non-invasive urothelial bladder tumours. Eur Urol. 2007; 52: 760-8.
• 17- Mumtaz S, Hashmi AA, Hasan SH, Edhi MM, Khan M. Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies. Int Arch Med. 2014; 7: 36.
• 18- Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014; 65: 218-26.
• 19- Abdul-Maksoud RS, Shalaby SM, Elsayed WS, Elkady S. Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer. Gene. 2016; 591: 320-6.
• 20- Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ et al. Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One. 2017; 12: e0179602.